Cubist Pharmaceuticals to Present at June 2009 Investor Conferences
LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Michael Bonney, President and CEO, will present on Wednesday June 10, 2009 at 3:30 p.m. Eastern Time, at the 8th Annual Needham Life Sciences Conference at The Palace Hotel in New York City. In addition, Robert Perez, EVP and COO, will present on Wednesday, June 17, 2009 at 12:30 p.m. Eastern Time, at the Jefferies 3rd Annual Healthcare Conference being held at the Mandarin Oriental Hotel in New York City. These presentations will include discussion of the company's business activities, financial outlook, and current news.
Also, David McGirr, SVP and CFO, will participate in a "fireside-chat" format on Tuesday, June 9th at 4:20 p.m. Eastern Time, at the Goldman Sachs Global Healthcare Conference at the Grand Hyatt Hotel in New York City.
Live webcasts of the presentations will be accessible through Cubist's website at www.cubist.com in the Investor Relations Conference Calendar section. The webcasts will be available on Cubist's website for a period of 30 days after the presentations.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM(R) I.V. (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV(TM)-1 and the planned CONSERV(TM)-2 -- for the reduction of blood loss during cardiothoracic surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other for infections caused by multi-drug resistant (MDR) Gram-negative bacteria. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.
Contact: Cubist Pharmaceuticals, Inc. Eileen C. McIntyre, 781-860-8533 Senior Director, Corporate Communications eileen.mcintyre@cubist.com or Weber Shandwick Tara Murphy, 617-520-7045 tmurphy@webershandwick.com
Also, David McGirr, SVP and CFO, will participate in a "fireside-chat" format on Tuesday, June 9th at 4:20 p.m. Eastern Time, at the Goldman Sachs Global Healthcare Conference at the Grand Hyatt Hotel in New York City.
Live webcasts of the presentations will be accessible through Cubist's website at www.cubist.com in the Investor Relations Conference Calendar section. The webcasts will be available on Cubist's website for a period of 30 days after the presentations.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM(R) I.V. (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV(TM)-1 and the planned CONSERV(TM)-2 -- for the reduction of blood loss during cardiothoracic surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other for infections caused by multi-drug resistant (MDR) Gram-negative bacteria. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.
Contact: Cubist Pharmaceuticals, Inc. Eileen C. McIntyre, 781-860-8533 Senior Director, Corporate Communications eileen.mcintyre@cubist.com or Weber Shandwick Tara Murphy, 617-520-7045 tmurphy@webershandwick.com